NEW! RJR has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.
Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.
The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.
THE IMMUNOGENICITY ERA – WHAT SHOULD WE KNOW ON ANTI-TNFS IN SPONDYLOARTHRITIS PATIENTS?
Spondyloarthritis (SpA) patients do not respond uniformly to TNF inhibitor therapy, some of them losing their beneficial evolution and becoming primary or secondary non-responders. Hence, questions have been raised whether this situation is linked to predictive genetic factors, individual characteristics or to disease activity. Studies have incriminated immunogenicity as being responsible for the loss or lack of response. It appears that the development of anti-drug antibodies leads to a decrease in drug levels with further impact on patients’ clinical state. This brief review aims to clarify some of the processes involved in the immunogenic phenomenon for patients with SpA, based on the current published literature.
Keywords: spondyloarthritis, anti-TNF therapy, immunogenicity, anti-drug antibodies